
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is expected to experience positive revenue growth in the coming years, driven by the potential success of denifanstat and TVB-3567 as effective and safe acne treatments. The company's focus on developing innovative therapies targeting FASN, a key pathway in various diseases, gives it a competitive edge in the market. Additionally, Sagimet's continued investment in research and development and partnerships with other biopharmaceutical companies further support its potential for growth and success in the pharmaceutical industry.
Bears say
Sagimet Biosciences is facing major competition in the acne treatment market, and their recent strategic pivot to prioritize acne over MASH is likely to face challenges in securing non-dilutive financing. While the positive Phase 3 trial results for denifanstat in acne are encouraging, the limited market penetration and slow projected growth may not justify the raised POS and peak sales estimates, making it difficult for the company to achieve its current high valuation. This, combined with the potential delays in the launch of denifanstat and concerns regarding TVB-3567 and the topical FASN program, contribute to a negative outlook on Sagimet's stock.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares